Correlations between serum kidney injury molecule-1, cystatin C and immunosuppressants: A cross-sectional study of renal transplant patients in Bahrain

Abstract

Renal transplant patients receive several immunosuppressive drug regimens that are potentially nephrotoxic for treatment. Serum creatinine is the standard for monitoring kidney function; however, cystatin C (Cys C) and kidney injury molecule-1 (KIM-1) have been found to indicate kidney injury earlier than serum creatinine and provide a better reflection of kidney function. Here, we assessed Cys C and KIM-1 serum levels in renal transplant patients receiving mycophenolate mofetil, tacrolimus, sirolimus, everolimus, or cyclosporine to evaluate kidney function. We used both the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2021 equation, which is based on creatinine and combined creatinine with Cys C, and the CKD-EPI 2012 equation, which is based on Cys C alone, to estimate glomerular filtration rate (GFR). Then, we assessed the association between serum KIM-1 and GFR < 90 mL per minute per 1.73 m². We observed significantly higher serum Cys C levels in patients with the elevated serum creatinine, compared with those with normal serum creatinine. The estimated GFRs based on creatinine were significantly higher than those based on the other equations, while a significant positive correlation was observed among all equations. Serum KIM-1 levels were negatively correlated with the estimated GFRs by the CKD-EPI Cys C and the combined creatinine with Cys C equations. A serum KIM-1 level above 0.71 ng/mL is likely to indicate GFR < 90 mL per minute per 1.73 m²). We observed a significant correlation between serum creatinine and Cys C in our renal transplant patients. Therefore, serum KIM-1 may be used to monitor renal function when using potentially nephrotoxic drugs in renal transplants.

Keywords

KIM-1 / cystatin C / mycophenolate mofetil / tacrolimus / everolimus / sirolimus / cyclosporine

Fundings

Part of the consumables used in the present study was obtained as a part of funding of a research study from College of Medicine and Medical Sciences, Arabian Gulf University (Grant No. G05/AGU-11/19).

Acknowledgments

None.

References

[1] Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal[J]. Am J Transplant, 2011, 11(3): 450-462. doi: 10.1111/j.1600-6143.2010.03283.x

[2] Swanson KJ, Aziz F, Garg N, et al. Role of novel biomarkers in kidney transplantation[J]. World J Transplant, 2020, 10(9): 230-255. doi: 10.5500/wjt.v10.i9.230

[3] Song J, Yu J, Prayogo GW, et al. Understanding kidney injury molecule 1: a novel immune factor in kidney pathophysiology[J]. Am J Transl Res, 2019, 11(3): 1219-1229. doi: 10.1002/mco2.110

[4] Yin C, Wang N. Kidney injury molecule-1 in kidney disease[J]. Ren Fail, 2016, 38(10): 1567-1573. doi: 10.1080/0886022X.2016.1193816

[5] Filler G, Bökenkamp A, Hofmann W, et al. Cystatin C as a marker of GFR - history, indications, and future research[J]. Clin Biochem, 2005, 38(1): 1-8. doi: 10.1016/j.clinbiochem.2004.09.025

[6] Rule AD, Larson TS, Bergstralh EJ, et al. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease[J]. Ann Intern Med, 2004, 141(12): 929-937. doi: 10.7326/0003-4819-141-12-200412210-00009

[7] Yang Y, Kim KY, Hwang I, et al. Cystatin C-based equation for predicting the glomerular filtration rate in kidney transplant recipients[J]. Transplant Proc, 2017, 49(5): 1018-1022. doi: 10.1016/j.transproceed.2017.03.050

[8] Malheiro J, Fonseca I, Martins LS, et al. A comparison between serum creatinine and cystatin C-based equations for estimation of graft function[J]. Transplant Proc, 2012, 44(8): 2352-2356. doi: 10.1016/j.transproceed.2012.07.032

[9] Jung YJ, Lee HR, Kwon OJ. Comparison of serum cystatin C and creatinine as a marker for early detection of decreasing glomerular filtration rate in renal transplants[J]. J Korean Surg Soc, 2012, 83(2): 69-74. doi: 10.4174/jkss.2012.83.2.69

[10] Kesiraju S, Chelluri LK, Gaddam S, et al. Assessment of renal function and acute rejection using Cystatin C and kidney injury Molecule-1 in renal transplant recipients[J]. Indian J Transplant, 2018, 12(1): 53-58. doi: 10.4103/ijot.ijot_42_17

[11] Morales JM, Andres A, Rengel M, et al. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation[J]. Nephrol Dial Transplant, 2001, 16 Suppl 1: 121-124. doi: 10.3390/molecules200713384

[12] de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future[J]. Am J Kidney Dis, 2000, 35(2): 333-346. doi: 10.1016/S0272-6386(00)70348-9

[13] Nankivell BJ, P'ng CH, O'Connell PJ, et al. Calcineurin inhibitor nephrotoxicity through the lens of longitudinal histology: comparison of cyclosporine and tacrolimus eras[J]. Transplantation, 2016, 100(8): 1723-1731. doi: 10.1097/TP.0000000000001243

[14] Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation[J]. N Engl J Med, 2007, 357(25): 2562-2575. doi: 10.1056/NEJMoa067411

[15] Flechner SM, Glyda M, Cockfield S, et al. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients[J]. Am J Transplant, 2011, 11(8): 1633-1644. doi: 10.1111/j.1600-6143.2011.03573.x

[16] Chhabra D, Skaro AI, Leventhal JR, et al. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus[J]. Clin J Am Soc Nephrol, 2012, 7(3): 504-512. doi: 10.2215/CJN.06940711

[17] Martins L, Ventura A, Branco A, et al. Cyclosporine versus tacrolimus in kidney transplantation: are there differences in nephrotoxicity?[J]. Transplant Proc, 2004, 36(4): 877-879. doi: 10.1016/j.transproceed.2004.03.083

[18] Peralta CA, Katz R, Sarnak MJ, et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications[J]. J Am Soc Nephrol, 2011, 22(1): 147-155. doi: 10.1681/ASN.2010050483

[19] Petrovic S, Bogavac-Stanojevic N, Lakic D, et al. Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery[J]. Biochem Med (Zagreb), 2015, 25(2): 262-271. doi: 10.11613/BM.2015.027

[20] Shardlow A, McIntyre NJ, Fraser SDS, et al. The clinical utility and cost impact of cystatin C measurement in the diagnosis and management of chronic kidney disease: a primary care cohort study[J]. PLoS Med, 2017, 14(10): e1002400. doi: 10.1371/journal.pmed.1002400

[21] Inker LA, Eneanya ND, Coresh J, et al. New creatinine- and cystatin C-based equations to estimate GFR without race[J]. N Engl J Med, 2021, 385(19): 1737-1749. doi: 10.1056/NEJMoa2102953

[22] Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C[J]. N Engl J Med, 2012, 367(1): 20-29.

[23] Delanghe JR, Speeckaert MM. Creatinine determination according to Jaffe-what does it stand for?[J]. NDT Plus. 2011, 4(2): 83-86.

[24] Marcén R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection[J]. Drugs, 2009, 69(16): 2227-2243. doi: 10.2165/11319260-000000000-00000

[25] Baker RJ, Mark PB, Patel RK, et al. Renal association clinical practice guideline in post-operative care in the kidney transplant recipient[J]. BMC Nephrol, 2017, 18(1): 174. doi: 10.1186/s12882-017-0553-2

[26] Xia T, Zhu S, Wen Y, et al. Risk factors for calcineurin inhibitor nephrotoxicity after renal transplantation: a systematic review and meta-analysis[J]. Drug Des Devel Ther, 2018, 12: 417-428. doi: 10.2147/DDDT.S149340

[27] Issa N, Kukla A, Ibrahim HN. Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence[J]. Am J Nephrol, 2013, 37(6): 602-612. doi: 10.1159/000351648

[28] Jeraiby M. Assessment of renal function using cystatin C and creatinine in Saudi patients after transplantation[J]. Ann Afr Med, 2021, 20(1): 59-63. doi: 10.4103/aam.aam_67_20

[29] Xirouchakis E, Marelli L, Cholongitas E, et al. Comparison of cystatin C and creatinine-based glomerular filtration rate formulas with ⁵¹Cr-EDTA clearance in patients with cirrhosis[J]. Clin J Am Soc Nephrol, 2011, 6(1): 84-92. doi: 10.2215/CJN.03400410

[30] den Bakker E, Musters M, Hubeek I, et al. Concordance between creatinine- and cystatin C-based eGFR in clinical practice[J]. Scand J Clin Lab Invest, 2021, 81(2): 142-146. doi: 10.1080/00365513.2021.1871776

[31] Delanaye P, Cavalier E, Cristol JP, et al. Calibration and precision of serum creatinine and plasma cystatin C measurement: impact on the estimation of glomerular filtration rate[J]. J Nephrol, 2014, 27(5): 467-475. doi: 10.1007/s40620-014-0087-7

[32] Bukabau JB, Sumaili EK, Cavalier E, et al. Performance of glomerular filtration rate estimation equations in Congolese healthy adults: the inopportunity of the ethnic correction[J]. PLoS One, 2018, 13(3): e0193384. doi: 10.1371/journal.pone.0193384

[33] den Bakker E, Gemke R, van Wijk JAE, et al. Combining GFR estimates from cystatin C and creatinine-what is the optimal mix?[J]. Pediatr Nephrol, 2018, 33(9): 1553-1563. doi: 10.1007/s00467-018-3973-8

[34] Gohda T, Kamei N, Koshida T, et al. Circulating kidney injury molecule-1 as a biomarker of renal parameters in diabetic kidney disease[J]. J Diabetes Investig, 2020, 11(2): 435-440. doi: 10.1111/jdi.13139

[35] Malyszko J, Koc-Zorawska E, Malyszko JS, et al. Kidney injury molecule-1 correlates with kidney function in renal allograft recipients[J]. Transplant Proc, 2010, 42(10): 3957-3959. doi: 10.1016/j.transproceed.2010.10.005

[36] Ayub S, Zafar MN, Aziz T, Iqbal T, Khan S, Rizvi SA. Evaluation of renal function by cystatin C in renal transplant recipients[J]. Exp Clin Transplant. 2014, 12(1): 37-40.

[37] Price SR, Gooch JL, Donaldson SK, et al. Muscle atrophy in chronic kidney disease results from abnormalities in insulin signaling[J]. J Ren Nutr, 2010, 20(S5): S24-S28. doi: 10.1053/j.jrn.2010.05.007